

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2018 December 21; 24(47): 5297-5414



**REVIEW**

- 5297 Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy  
*Li H, Huang MH, Jiang JD, Peng ZG*

**MINIREVIEWS**

- 5312 Split liver transplantation: Current developments  
*Hackl C, Schmidt KM, Süsal C, Döhler B, Zidek M, Schlitt HJ*
- 5322 Novel oral-targeted therapies for mucosal healing in ulcerative colitis  
*Antonelli E, Villanacci V, Bassotti G*
- 5331 Percutaneous ablation for perivascular hepatocellular carcinoma: Refining the current status based on emerging evidence and future perspectives  
*Kang TW, Lim HK, Cha DI*

**ORIGINAL ARTICLE****Basic Study**

- 5338 *Piwi like RNA-mediated gene silencing 1* gene as a possible major player in gastric cancer  
*Araújo T, Khayat A, Quintana L, Calcagno D, Mourão R, Modesto A, Paiva J, Lima A, Moreira F, Oliveira E, Souza M, Othman M, Liehr T, Abdelhay E, Gomes R, Santos S, Assumpção P*
- 5351 Relationship between *Fusobacterium nucleatum*, inflammatory mediators and microRNAs in colorectal carcinogenesis  
*Proença MA, Biselli JM, Succi M, Severino FE, Berardinelli GN, Caetano A, Reis RM, Hughes DJ, Silva AE*
- 5366 Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine  
*Amic F, Drmic D, Bilic Z, Krezic I, Zizek H, Peklic M, Klicek R, Pajtak A, Amic E, Vidovic T, Rakic M, Milkovic Perisa M, Horvat Pavlov K, Kokot A, Tvrdeic A, Boban Blagaic A, Zovak M, Seiwert S, Sikiric P*
- 5379 Novel screening test for celiac disease using peptide functionalised gold nanoparticles  
*Kaur A, Shimoni O, Wallach M*

**Case Control Study**

- 5391 Analyzing predictors of graft survival in patients undergoing liver transplantation with donors aged 70 years and over  
*Caso-Maestro O, Jiménez-Romero C, Justo-Alonso I, Calvo-Pulido J, Lora-Pablos D, Marcacuzco-Quinto A, Cambra-Molero F, García-Sesma A, Pérez-Flecha M, Muñoz-Arce C, Loinaz-Seguro C, Manrique-Municio A*

**Retrospective Cohort Study**

- 5403** Five years of fecal microbiota transplantation - an update of the Israeli experience

*Greenberg SA, Youngster I, Cohen NA, Livovsky DM, Strahilevitz J, Israeli E, Melzer E, Paz K, Fliss-Isakov N, Maharshak N*

**ABOUT COVER**

Editorial board member of *World Journal of Gastroenterology*, Haruhiko Sugimura, MD, PhD, Professor, Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan

**AIMS AND SCOPE**

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 642 experts in gastroenterology and hepatology from 59 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

**INDEXING/ABSTRACTING**

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents<sup>®</sup>/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch<sup>®</sup>), Journal Citation Reports<sup>®</sup>, Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2018 edition of Journal Citation Reports<sup>®</sup> cites the 2017 impact factor for *WJG* as 3.300 (5-year impact factor: 3.387), ranking *WJG* as 35<sup>th</sup> among 80 journals in gastroenterology and hepatology (quartile in category Q2).

**EDITORS FOR THIS ISSUE**

Responsible Assistant Editor: Xiang Li  
Responsible Electronic Editor: Yan Huang  
Proofing Editor-in-Chief: Lian-Sheng Ma

Responsible Science Editor: Xue-Jiao Wang  
Proofing Editorial Office Director: Ze-Mao Gong

**NAME OF JOURNAL**  
*World Journal of Gastroenterology*

**ISSN**  
ISSN 1007-9327 (print)  
ISSN 2219-2840 (online)

**LAUNCH DATE**  
October 1, 1995

**FREQUENCY**  
Weekly

**EDITORS-IN-CHIEF**  
Andrzej S Tarnawski, MD, PhD, DSc (Med),  
Professor of Medicine, Chief Gastroenterology, VA  
Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach, CA 90822, United States

**EDITORIAL BOARD MEMBERS**  
All editorial board members resources online at <https://www.wjgnet.com/1007-9327/editorialboard.htm>

**EDITORIAL OFFICE**  
Ze-Mao Gong, Director  
*World Journal of Gastroenterology*  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
Help Desk: <https://www.f0publishing.com/helpdesk>  
<https://www.wjgnet.com>

**PUBLISHER**  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <https://www.f0publishing.com/helpdesk>  
<https://www.wjgnet.com>

**PUBLICATION DATE**  
December 21, 2018

**COPYRIGHT**  
© 2018 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**  
Full instructions are available online at <https://www.wjgnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**  
<https://www.f0publishing.com>

## Basic Study

# ***Piwi like RNA-mediated gene silencing 1* gene as a possible major player in gastric cancer**

Taíssa Araújo, André Khayat, Luciana Quintana, Danielle Calcagno, Ronald Mourão, Antônio Modesto, Juliana Paiva, Adhara Lima, Fabiano Moreira, Edivaldo Oliveira, Michel Souza, Moneeb Othman, Thomas Liehr, Eliana Abdelhay, Renata Gomes, Sidney Santos, Paulo Assumpção

Taíssa Araújo, André Khayat, Luciana Quintana, Danielle Calcagno, Ronald Mourão, Antônio Modesto, Juliana Paiva, Adhara Lima, Fabiano Moreira, Sidney Santos, Paulo Assumpção, Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém 66073-000, Brazil

Edivaldo Oliveira, Michel Souza, Laboratório de Cultura de Tecidos e Citogenética, Instituto Evandro Chagas, Belém 66087-082, Brazil

Moneeb Othman, Thomas Liehr, Institute of Human Genetics, Universitätsklinikum Jena, Jena 07747, Germany

Eliana Abdelhay, Renata Gomes, Laboratório de Célula Tronco, Centro de Transplante de Medula Óssea, Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro 20230-130, Brazil

ORCID number: Taíssa Araújo (0000-0002-1716-4445); André Khayat (000-0002-3451-6369); Luciana Quintana (0000-0003-3261-910X); Danielle Calcagno (0000-0002-4429-2573); Ronald Mourão (0000-0001-5582-4961); Antônio Modesto (0000-0003-1854-0358); Juliana Paiva (0000-0002-2082-2250); Adhara Lima (0000-0001-6315-2392); Fabiano Moreira (0000-0002-2799-3546); Edivaldo Oliveira (0000-0001-6315-3352); Michel Souza (0000-0003-1038-6448); Moneeb Othman (0000-0002-0743-1191); Thomas Liehr (0000-0003-1672-3054); Eliana Abdelhay (0000-0001-5166-0832); Renata Gomes (0000-0001-7590-0335); Sidney Santos (0000-0002-8622-9417); Paulo Assumpção (0000-0003-3846-8445).

**Author contributions:** Araújo T and Khayat A contributed equally to this work; Araújo T and Khayat A performed the majority of experiments; Moreira F, Oliveira E and Souza M analyzed the data; Modesto A, Paiva J and Lima A performed the molecular investigations; Quintana L, Calcagno D and Mourão R participated equally in cell culture management; Othman M and Liehr T performed molecular cytogenetics experiments; Abdelhay E and Gomes R performed proteomic assay; Santos S and Assumpção P designed and coordinated the research; Araújo T, Khayat A and Quintana L wrote the paper.

Supported by Fundação Amazônia de Amparo a Estudos e Pesquisa (FAPESPA), No. 174/2014.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Corresponding author to:** Paulo Assumpção, MD, MSc, PhD, Academic Research, Adjunct Professor, Surgical Oncologist, Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Rua dos Mundurucus 4487, Belém 66073-000, Brazil. [assumpcaopp@gmail.com](mailto:assumpcaopp@gmail.com)  
Telephone: +55-91-984171112

**Received:** August 14, 2018

**Peer-review started:** August 14, 2018

**First decision:** August 31, 2018

**Revised:** September 7, 2018

**Accepted:** October 5, 2018

**Article in press:** October 5, 2018

**Published online:** December 21, 2018

## Abstract

### AIM

To establish a permanent *piwi like RNA-mediated gene*



*silencing 1 (PIWIL1)* gene knockout in AGP01 gastric cancer cell line using CRISPR-Cas9 system and analyze phenotypic modifications as well as gene expression alterations.

## METHODS

CRISPR-Cas9 system used was purchased from Dharmacon GE Life Sciences (Lafayette, CO, United States) and permanent knockout was performed according to manufacturer's recommendations. Wound-healing assay was performed to investigate the effect of *PIWIL1* knockout on migration capability of cells and Boyden chamber invasion assay was performed to investigate the effect on invasion capability. For the gene expression analysis, a one-color microarray-based gene expression analysis kit (Agilent Technologies, Santa Clara, CA, United States) was used according to the protocol provided by the manufacturer.

## RESULTS

*PIWIL1* gene knockout caused a significant decrease in AGP01 migration capacity as well as a significant decrease in cell invasiveness. Moreover, functional analysis based on grouping of all differentially expressed mRNAs identified a total of 35 genes (5 up-regulated and 30 down-regulated) encoding proteins involved in cellular invasion and migration. According to current literature, 9 of these 35 genes (*DOCK2*, *ZNF503*, *PDE4D*, *ABL1*, *ABL2*, *LPAR1*, *SMAD2*, *WASF3* and *DACH1*) are possibly related to the mechanisms used by *PIWIL1* to promote carcinogenic effects related to migration and invasion, since their functions are consistent with the changes observed (being up- or down-regulated after knockout).

## CONCLUSION

Taken together, these data reinforce the idea that *PIWIL1* plays a crucial role in the signaling pathway of gastric cancer, regulating several genes involved in migration and invasion processes; therefore, its use as a therapeutic target may generate promising results in the treatment of gastric cancer.

**Key words:** Gastric cancer; *Piwi like RNA-mediated gene silencing 1*; CRISPR-Cas9; Migration; Invasion

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** *Piwi like RNA-mediated gene silencing 1 (PIWIL1)* gene emerged as an interesting target for gastric cancer, as it is expressed in cancer, stem and germ cells, but it is absent in normal somatic tissue. Our results propose that *PIWIL1* plays a crucial role in the signaling pathway of gastric cancer, regulating several genes involved in migration and invasion processes; therefore, its use as a therapeutic target may generate promising results in the treatment of gastric cancer.

Liehr T, Abdelhay E, Gomes R, Santos S, Assumpção P. *Piwi like RNA-mediated gene silencing 1* gene as a possible major player in gastric cancer. *World J Gastroenterol* 2018; 24(47): 5338-5350  
URL: <https://www.wjgnet.com/1007-9327/full/v24/i47/5338.htm>  
DOI: <https://dx.doi.org/10.3748/wjg.v24.i47.5338>

## INTRODUCTION

Gastric cancer is a major contributor to global cancer burden, being the third leading cause of cancer death worldwide and in both sexes<sup>[1]</sup>. This type of cancer is thought to be consequence of a multi-step process, resulting from different genetic and epigenetic changes. Specifically, dysfunction of oncogenes and tumor suppressor genes contributes to this malignant disease, and many candidate genes have been implicated to serve as gastric cancer biomarkers<sup>[2]</sup>.

In this context, the *piwi like RNA-mediated gene silencing 1 (PIWIL1)* gene, located in 12q24.33 and having 22 exons, became an attractive target for gastric cancer treatment. *PIWIL1* protein is expressed at increased levels in cancer tissues, stem cells and germ cells, but it has been shown to be absent in normal somatic tissues. This means that it could be a potential target for therapy, since most non-cancer cells would not be affected by cytotoxic effects<sup>[3-7]</sup>.

*PIWIL1* plays a key role in tumor cell viability, migration and invasion, and its expression is associated with the maintenance of stem-like characteristics of tumors, which in turn contribute to more severe histological grade, advanced stage and worse clinical outcome<sup>[8-10]</sup>.

Wang *et al.*<sup>[11]</sup> showed that expression of *PIWIL1* in gastric cancer tissue was significantly higher than in adjacent-to-tumor tissue (tumor front). They also demonstrated that patients with a lower expression of *PIWIL1* presented a significant better overall survival rate compared to patients with a higher expression levels. Additionally, the 5-year survival rate of patients with a higher expression level of *PIWIL1* was significantly lower (36.5% vs 67.6%).

Liu *et al.*<sup>[12]</sup> reported that expression of *PIWIL1* progressively increases during cancer development. The expression ratio in normal gastric tissues, atrophic gastritis, intestinal metaplasia and gastric cancers varied from 10% to 76%.

To further investigate the potential functions of the *PIWIL1* gene, Liu *et al.*<sup>[12]</sup> also silenced *PIWIL1* by antisense or short hairpin RNA and noted that suppression of this gene inhibited the growth of gastric cancer cells and induced G2/M arrest. Although relevant information regarding the possible role of *PIWIL1* in gastric cancer carcinogenesis is provided by the current literature, the exact molecular mechanisms involved in this carcinogenic process remain unclear.

A recently introduced technology, based on the adaptive immune system of prokaryotes and known as type II clustered, regularly interspaced, short palindromic

Araújo T, Khayat A, Quintana L, Calcagno D, Mourão R, Modesto A, Paiva J, Lima A, Moreira F, Oliveira E, Souza M, Othman M,

repeats (CRISPR)/associated protein (Cas), has been demonstrated to cleave double-stranded DNA and has emerged as a relevant genome editing tool<sup>[13-15]</sup>.

This technology can be used both to perform permanent gene knockouts and the site-specific integration of a gene (knock-in)<sup>[16-19]</sup>. Importantly, it allows for the permanent silencing of the target gene, and it also creates a stable and permanent cell line with the desired modification<sup>[14,16]</sup>.

Here we applied CRISPR/Cas9 technology for the first time to knockout *PIWIL1* gene in a gastric cancer cell line and analyzed its phenotypic modifications.

## MATERIALS AND METHODS

### Cell lines

The human gastric cancer cell line AGP01 was maintained in DMEM-F12 medium supplemented with 10% fetal bovine serum. The cell culture grew attached to a plastic flask in a monolayer in a humidified incubator maintained at 37 °C and 5% CO<sub>2</sub>.

The AGP01 cell line was established by our research group in 2009<sup>[20]</sup> from cancer cells present in the ascitic fluid of a female individual with intestinal gastric cancer, located at the antrum and the body region of the stomach, and staged as T3N2M1. The cell line was tested and authenticated by conventional cytogenetics<sup>[20]</sup>. Recently, the AGP01 cell line was tested by multicolor-fluorescence *in situ* hybridization (FISH), and results are presented here.

### 24-color-FISH using all human whole chromosome painting probes

24-color-FISH using simultaneous all human whole chromosome painting (WCP) probes was done as previously reported<sup>[21,22]</sup>. A total of 20 metaphases was analyzed, using a fluorescence microscope (Axio Imager Z1 mot; Carl Zeiss AG, Oberkochen, Germany) equipped with appropriate filter sets to discriminate between a maximum of five fluorochromes and the counterstain DAPI; the latter was used to induce a GTG-like banding pattern. Image capturing and processing were carried out using ISIS imaging system (MetaSystems, Altlussheim, Germany).

### Targeted knockout of *PIWIL1* using the CRISPR-Cas9 system

The CRISPR-Cas9 system used was purchased from Dharmacon GE Life Sciences (Lafayette, CO, United States). First,  $1 \times 10^4$  AGP01 cells/well were seeded in DMEM-F12 medium to a 96-well plate for 24 h. Subsequently, transfection was performed using CR-0046-03-005 (Dharmacon GE Life Sciences) for 48 h. For the transfection procedure, a solution containing 1 µL of the CRISPR RNAs (crRNAs) mixed with the trans-activating small RNA, 2 µL of Cas9 and 7 µL of DMEM-F12 medium (for each well) was prepared first. In another tube, 0.4 µL of DharmaftecDUO and 9.6 µL of DMEM-F12 medium (to each well) were added.

The solutions were then incubated for 5 min at room temperature before being combined. After combining, the solution was incubated for 20 min at room temperature, and finally 80 µL of DMEM-F12 medium/10% fetal calf serum (FCS) (per well) was added. At the end of the transfection, all contents (from each well) were transferred to a 24-well plate containing DMEM-F12 medium/10% FCS/1% pen-strep.

After 24 h, samples were treated with 6 µg/mL of puromycin for 72 h to select the resistant clones. Next, 40 cells were plated per well in a 6-well plate to isolate the clones by the filter paper method.

This method consists of using a cut and autoclaved piece of filter paper so that it, after being soaked in trypsin, can be positioned above a single colony of cells that has grown from an isolated cell, allowing for the collection of this clone. Subsequently, each clone grew in a separate well in a 6-well plate, so it could reach the confluence needed to perform DNA extraction and sequencing.

### Sequencing

DNA was extracted using the Wizard Genomic DNA Purification Kit (Promega Corporation, Madison, WI, United States) according to the manufacturer's instructions. For PCR, specific primers targeting the binding region of the purchased crRNA were constructed using the online program Primer3 (Supplementary Table 1).

The quantities of the reagents used in the PCR for a final volume of 12 µL were as follows: 6.25 µL of nuclease-free H<sub>2</sub>O, 0.5 µL of forward primer (10 ng/µL), 0.5 µL of reverse primer (ng/µL), 4.25 µL of GoTaq Colorless Master Mix 2× (Promega Corporation) and 1 µL of DNA (10 ng/µL).

The conditions using the MasterCycler Gradient thermal cycler (Eppendorf, Hamburg, Germany) were 1 cycle at 95 °C for 3 min for initial denaturation followed by 35 cycles consisting of denaturation at 94 °C for 2 min, primer annealing at 59 °C for 1 min and extension at 70 °C for 2 min, ending with 1 cycle at 70 °C for a final extension for 30 min.

For direct sequencing of the PCR product, the quantities of the reagents used for a final volume of 20 µL were as follows: 15 µL of nuclease-free water, 0.5 µL of forward or reverse primer (10 ng/µL), 0.5 µL of Big Dye, 3 µL of Save Money and 1 µL of the PCR reaction. For this reaction, the ABI PRISM Big Dye Terminator 3.1 Cycle Sequencing Kit (Applied Biosystems, Hercules, CA, United States) was used.

The sequencing was performed using the MasterCycler Gradient (Eppendorf) thermal cycler according to the following 25-cycle thermocycling conditions: denaturation at 96 °C for 50 s, primer annealing at 59 °C for 1 min and extension at 60 °C for 4 min, ending with 1 cycle at 4 °C for 5 min.

After this procedure, a precipitation step was carried out in order to purify the product of the reaction before continuing. For this step, samples were washed with

70% isopropanol and 70% ethanol. Subsequently, sequencing was performed using the ABI Prism 3500 DNA Sequencer (Applied Biosystems). The methodology used was based on the biochemical synthesis of the DNA strand by the Sanger method.

### Sequencing analysis

Reference sequence for exon 15 in the *PIWIL1* gene was obtained from the National Center for Biotechnology Information (NCBI) and compared with the DNA sequence of the modified cell line as well as the negative control (cell line without the gene knockout). To infer the effect of changes in protein synthesis, we applied Gene Runner v.3.05 (Hastings Software Inc., Hastings, NY, United States; <http://www.generunner.com>).

### Wound-healing assay

Cells were grown in 12-well plates at a density of  $2 \times 10^5$  cells/well and maintained for 24 h in 5% CO<sub>2</sub> at 37 °C. After this period, cells were injured with a 10 µL tip in the center of each well. The medium was then removed to eliminate suspended cells, and wells were washed with 1 × phosphate buffered saline before fresh DMEM-F12 medium/10% FCS/1% pen-strep was added again.

The behavior of cells was observed and photographed immediately after injury and at 6 h, 12 h and 24 h after injury. All experiments were performed in triplicate.

### Boyden chamber invasion assay

Boyden inserts (8 µm pores) (BD Biosciences™, Franklin Lakes, NJ, United States) were coated with 200 µL of Matrigel (10-13 mg/mL) in 12-well plates. Cells ( $2 \times 10^5$ ) were seeded in the upper chamber in 1 mL of DMEM without fetal bovine serum. In the lower chamber, DMEM-F12 medium/10% FCS/1% pen-strep was added, functioning as a chemoattractant for the cells present in the upper chamber.

After 48 h, the remaining cells above the filter were removed by scraping with a sterile swab. The cells at the bottom of the filter were fixed with 4% paraformaldehyde and stained with Giemsa. Cells were photographed and analyzed using a light microscope and counted in optical fields (100 ×). All experiments were performed in triplicate.

### Total RNA extraction

The mRNA extraction was performed using Promega's Total RNA Isolation System kit, according to the manufacturer's specifications. AGP01 and AGP01 *PIWIL1* knockout cells were prepared for mRNA extraction. Samples were lysed with lysis buffer containing beta-mercaptoethanol and then diluted in RNA dilution buffer. The samples were centrifuged for 10 min at maximum speed. Then, 95% ethanol was added to ensure adequate membrane binding conditions.

The samples were then transferred to centrifuge

columns where the RNA could bind the membrane of the column, facilitating washing to eliminate possible contaminants as well as favoring the extraction of high quality of total RNA.

At the end of the procedure, the RNA was diluted in 60 µL of nuclease-free water. The total RNA was quantified using a Nanodrop spectrophotometer ND-1000 UV-VIS version 3.2.1 (Nanodrop Technologies, Wilmington, DE, United States). The RNA quality was also evaluated by analyzing the A<sub>260</sub>/A<sub>280</sub> ratio according to the manufacturer's specifications. Purified RNA was stored at -80 °C for the microarray expression assay.

### Microarray expression

For the microarray assay, a one-color microarray-based gene expression analysis kit (Agilent Technologies, Santa Clara, CA, United States) was used according to the protocol provided by the manufacturer. The gene expression profile was evaluated in both cell lines (AGP01 with and without *PIWIL1* knockout).

The total RNA obtained during the extraction phase was used as the template for the synthesis of the first cDNA strand by reverse transcription using T7 RNA polymerase. Synthesis of the second cDNA strand was used as the template for the *in vitro* transcription reaction for cRNA production. The cRNA was then incorporated into the fluorochrome 3-cyanine (Cy-3) using the Low Input Quick Amp Labeling kit (Agilent Technologies) according to the protocol provided by the manufacturer. Thereafter, the cRNA purification process was carried out.

The cRNA was quantified by a spectrophotometer (pmol/L), by which it was possible to analyze the absorbance ratio (260 nm/280 nm) and the cRNA (ng/µL) concentration in each sample. After, hybridization was performed for 17 h in a hybridization chamber at 65 °C at 10 rpm. After this period, the slide was washed and immediately scanned in the Agilent G4900DA SureScan Microarray System.

The following setup was used to scan the microarray slides for one color: scan region of 61 mm × 21.6 mm, 5 µm scan resolution, dye channel of green. Next, the images were obtained by using Feature Extraction v10.10 software, and the data were analyzed with GeneSpring GX 9.0 and IPATHWAYGUIDE (Advaita Bioinformatics Company, Plymouth, MI, United States) programs. Gene identification followed a restriction criterion with a fold-change of > 2.

### Differential expression and gene ontology enrichment analysis

To identify differentially expressed (DE) mRNAs, we compared the probes' expression profiles before and after *PIWIL1* knockout. Probes with a mean fold-change < 0.5 and a mean fold-change of > 2 [ $|\text{Log}_2(\text{fold-change})| > 1$ ] were selected for differential analysis. Student's *t* test was performed in 1222 selected probes, false discovery rate adjustment<sup>[23]</sup> was performed,






Figure 1 AGP01 cell line multicolor-FISH showing several chromosomal changes, including the monosomy of chromosome 12, where the *PIWIL1* gene is located.

and genes with an adjusted *P*-value of  $< 0.05$  were tagged as DE. For the volcano plot, the fold-change and the *P*-value of all probes were used, and probes were tagged as DE following the previous criteria. Gene ontology enrichment was performed using org. Hs.eg.db<sup>[24]</sup> and Gostats<sup>[25]</sup> R libraries. All graphical and statistical analyses were performed in the R platform (R Core Team, 2017, Vienna, Austria; <https://www.R-project.org/>).

## RESULTS

### 24-color-FISH using all human WCP probes

24-color-FISH using all human WCP probes revealed in AGP01 cell line a complex karyotype as follows: 63,XX,inv(1)(p12q43),der(1)(1pter->1 p 1 2 : : 1 q 4 3 -> 1 p 1 2 : : 9 p 1 2 ->9pter),+der(1)t(1;12)(q21;q12),+del(1)(p12),+del(2)(p12),+der(2)t(2;8)(p12;q11.2),inv(3)(p21q13)x2,+inv(3)(p21q13),+der(3)t(3;5)(p14;q13),t(4;14)(p12;q11.2),dic(4;12)(p15;q12),+der(4)t(2;4)(p or q;q12),del(5)(p13)x2,+der(5)x2,del(6)(q12)x2,+del(6)(p21),inv(7)(p12;q11.2),der(7),der(9)t(9;acro)(p21;p12),der(9)t(6;9)(p12;p12),t(13;13)(p10),der(15)(:q13->p11::p11->qter),-15,der(16)t(X;16)(q or p;q23),+der(16)t(12;16)(q12;q23),21p+,t(22;22)(p10) (Figure 1).

From the analysis, we verified that the unique chromosome 12 (where *PIWIL1* gene is located) remains intact, without translocations or derivative chromosomes. It is important to note that the monosomy of chromosome 12 agrees with the sequencing result, since the 7 bp insert sequence was observed in hemizygous status.

### Targeted knockout of the *PIWIL1* gene using the CRISPR-Cas9 system

*PIWIL1* gene knockout was successful, as determined by Sanger sequencing. The latter revealed an insertion of 7 adenines in the *PIWIL1* gene sequence (Figure 2), which caused a frameshift mutation that impaired protein synthesis.

Prediction of the encoded protein indicated a premature stop codon (Figure 3), suggesting that this insertion generates a truncated protein consisting of 573 amino acids (the wild-type contains 861) with a loss-of-function phenotype, which means that knockout was efficient.

Notably, the *PIWIL1* knockout cell line remained viable and could be used for further experiments.

### Wound-healing assay

The *PIWIL1* gene knockout caused a significant decrease in AGP01 migration capacity after 24 h ( $P < 0.01$ ; Figure 4), which is consistent with the fact that this protein is related to various pathways that regulate cell motility.

### Boyden chamber invasion assay

Also, *PIWIL1* gene knockout caused a significant decrease in AGP01 invasiveness ( $P < 0.001$ ; Figure 5), which is also consistent with the fact that this protein is related to various pathways that regulate cell motility.

### mRNA array and gene ontology enrichment

**Differential analysis:** By comparing expression profiles after *PIWIL1* permanent knockout in the AGP01 cell line, a total of 251 mRNA were found to be DE




Figure 2 Electropherograms showing the insertion of seven adenines in the *PIWIL1* gene sequence after using the CRISPR-Cas9 system (B) in comparison with the reference sequence of the negative control (A).

[adjusted  $P$ -value of  $< 0.05$  and  $|\log_2(\text{Fold-Change})| > 1$ ]. A total of 43 mRNA probes were up-regulated and 208 were down-regulated (Figure 6). The DE genes are described in Supplementary Table 2.

We performed a functional analysis by grouping all DE mRNAs. This approach revealed that a total of 35 genes (five up-regulated and 30 down-regulated) encoded proteins involved in invasion and migration cellular processes (Supplementary Figure 1; Supplementary Tables 3 and 4).

According to the current literature, 9 of these 35 genes (*DOCK2*, *ZNF503*, *PDE4D*, *ABL1*, *ABL2*, *LPAR1*, *SMAD2*, *WASF3* and *DACH1*) are possibly related to the mechanisms used by *PIWIL1* to promote carcinogenic effects related to migration and invasion, since their functions are consistent with the changes observed (being up- or down-regulated after knockout).

## DISCUSSION

Evidence indicating that *PIWIL1* is an oncogene that regulates several cellular mechanisms important for the carcinogenic process of many types of cancers is rising in recent years. *PIWIL1* seems to be especially implicated in proliferating activity of cancer cells<sup>(8,10,26,27)</sup>.

Here, we introduce a new gastric cell line, *i.e.*, AGP01, and provide a first description of its karyotype. As is usual for cancer cell lines, there were slight changes from

861 aa  
3591  
nucleotides,  
1196 amino  
acids

```

1 YWAYGVQTRG RRPGGGVHPP GKRAPVARCP RVPGLSLGPA PKARWARAEG GPGRSAARRD
61 LRGSRWGCWP RAEVQGPGLG RGQRSKK*KT MTGRARARAR GRARGQETAQ LVGSTASQQP
121 GYIQPRPQPP PAEGELFGRG RQRGTAGGTA KSQGLQISAG FQELSLAERG GRRRDFHDLG
181 VNTRQNLDHV KESKTGSSGI IVRLSTNHFR LTRPQWALY QYHIDYNPL EARRLSALL
241 FQHEDLIGKC HAFDGTILFL PKRLQQKYTE VFSKTRNGED VRITITLTNE LPPTSPTCLQ
301 FYNIFRRL KIMNLQQIGR NYNPNPID IPSHRLVIWP GFTTSILQYE NSIMLCTDVS
361 HKVLRSETVL DFMFNFYHQT EEHKFQEQVS KELIGLVVLT KYNNKTYRVD DIDWDQNPKS
421 TFKKADGSEV SFLEYRKQY NQEITDLKQP VLVSQPKRRR GPGGTLPGPA MLIPELCYLT
481 GLTDKMRNDF NVNKDLAVHT RLTPQQRRE VGRLLIDYHK NDNVQREL RD WGLSFDSNLL
541 SFSGRILQTE KIHQGGKTFD YNPQFADWSK ETRGAPLISV KPLDNWLLIY TRRNYEAANS
601 LIQNLFKVTP AMGMQMRKAI MIEVDDRTEA YLRVLQKKVT ADTQIVVCLL SSNRKDKYDA
661 IKKYLCTDCP TPSQCVVART LGKQQTVMAI ATKIALQNC KNGGELWRVD IPLKLVIVG
721 IDCYHDMTAG RRSIAGFVAS INEGMTRWFS RCIFQDRGQE LVDGLKVCLQ AALRAWNSCN
781 EYMPRIIVY RDGVGDGQLK TLVNYEVPQF LDCLKSIGRG YNPLTVIVV KKRNVTRFFA
841 QSGGRLQNP L PGTVIDVEVT RPEWYDFIV SQAVRSQSVS PTHYNYIYD SGLKPDHIQR
901 LTYKLCHYY NWPGVIRVPA PCQYAHKLAFL LVGQSIHREP NLSLSNRLYY L*PAEDDAAA
961 FLFEMTLGFF *AFIYFFNC YLSG*NLGRG LGDLAFYF*H CYPASLFYT *KLRFYILSS
1021 CFS*IFCEHF FVYFEEMWIR YLVV*NRLSE SI*NVFGDLL KRTFRSEQVL LINLY*LYF*
1081 DTCFEFGDK RRVKGC SLQ *VGFQLIS*R *KVLNLYT RYRRKYA*FL FGRGARLYGS
1141 KKNIEFN*IV QRNLRFLFNK KGHE*ISILT LLFILFWND M*ILFVKN*N* CDCHLI

```

Wild-type *PIWIL1* protein sequence

573 aa  
3598  
nucleotides,  
1199 amino  
acids

```

1 YWAYGVQTRG RRPGGGVHPP GKRAPVARCP RVPGLSLGPA PKARWARAEG GPGRSAARRD
61 LRGSRWGCWP RAEVQGPGLG RGQRSKK*KT MTGRARARAR GRARGQETAQ LVGSTASQQP
121 GYIQPRPQPP PAEGELFGRG RQRGTAGGTA KSQGLQISAG FQELSLAERG GRRRDFHDLG
181 VNTRQNLDHV KESKTGSSGI IVRLSTNHFR LTRPQWALY QYHIDYNPL EARRLSALL
241 FQHEDLIGKC HAFDGTILFL PKRLQQKYTE VFSKTRNGED VRITITLTNE LPPTSPTCLQ
301 FYNIFRRL KIMNLQQIGR NYNPNPID IPSHRLVIWP GFTTSILQYE NSIMLCTDVS
361 HKVLRSETVL DFMFNFYHQT EEHKFQEQVS KELIGLVVLT KYNNKTYRVD DIDWDQNPKS
421 TFKKADGSEV SFLEYRKQY NQEITDLKQP VLVSQPKRRR GPGGTLPGPA MLIPELCYLT
481 GLTDKMRNDF NVNKDLAVHT RLTPQQRRE VGRLLIDYHK NDNVQREL RD WGLSFDSNLL
541 SFSGRILQTE KIHQGGKTFD YNPQFADWSK ETRGAPLISV KPLDNWLLIY TRRNYEAANS
601 LIQNLFKVTP AMGMQMRKAI MIEVDDRTEA YLRVLQKKVT ADTQIVVCLL SSKKKSEGQI
661 RCY*KIPVYR LPYPKSVCGG PNLRTQANCH GHCKYDCPTD ELQDGRRALE GGHPPPEARDD
721 RWHRLLP*HD SWAEVNRRIC CQHQRDDPL VTLTHISG*R TGAGRWASL PASGSEGLE*
781 LQ*VHAQPDH RVPWRRRRR AENTGELRSA TVFGLSKIHW *RLQP*TNGN CGEEKSEHQI
841 FCSVWRKTS STSWNSY*CR GYQTRV*LF YREPGCEKW* CFSHTLQCHL *QQRPEARPH
901 TALDLQAVPH LLQLARCHSC SCSLPVRPQA GFSCWPEYSQ RAKSVTVKPP LLPLTCRRRC
961 SRSF*NDFF IFLSFYLLFF *LLSFW*KLK KGIRRSILF LALLFTGLFI LYVKIKILYF
1021 IRLFLIDL* AFFCLF*RNVD KILGSIKQT L*EYLKCVWR FT*TYFQE*A SPTYKPILTL
1081 FLRYLF*I*R R*EA*SRMLT TTIGGVSAHI LKIKGTII*P IHKIQEKICL IFIWQGG*VV
1141 WE*KKH*KFL NCPKKHFKTL *QKRP*VNLY INITIYFVLE LGHDSICYKI KLM*LSPYL

```

Predict sequence of *PIWIL1* after knockout

Figure 3 Amino acid sequences of the wild-type *PIWIL1* protein and the *PIWIL1* protein after the insertion of seven adenines by the CRISPR-Cas9 system.


cell to cell concerning number of chromosomes or single cell chromosomal rearrangements<sup>[28]</sup>. The here-given karyotype was the most frequently observed one. Interestingly, inversions, dicentrics and reciprocal translocations of homologous acrocentric (#13, #15, #22) was observed. Overall, gain of the following regions was present: #1, #3, large parts of #2 and #5, 8q11.2 to 8qter, 12pter to 12q12. Besides, the following regions were under-represented: 2pter to 2p12, 9pter to 9p12, 15q12 to 15qter. These imbalances are in concordance with the literature<sup>[29]</sup>.

In AGP01, we performed for the first time an *in*

*vitro* knockout experiment of *PIWIL1* gene using the CRISPR-Cas9 system. It could be shown that absence of this gene significantly impairs migration and invasion capacity of AGP01 cells. Thus, the AGP01 cell line behaves like that previously reported for gastric cancer cells<sup>[12]</sup> or lung adenocarcinoma<sup>[26]</sup>. Together, these studies suggest that *PIWIL1* expression is strongly associated with an increased aggressiveness of cancer cells.

According to Wang *et al.*<sup>[30]</sup>, one of the mechanisms by which *PIWIL1* regulates the migration and invasion of cancer cells is by promoting the expression of MMP2





**Figure 4** Analysis of the migration capacity of the AGP01 cell line with and without *PIWIL1* gene knockout. T0: Immediately after injury; T6: 6 h after injury; T12: 12 h after injury; T24: 24 h after injury. NC: Negative control. <sup>a</sup>*P* < 0.01. Two-way ANOVA, Bonferroni post-test. Photomicrography of AGP01 cell migration. A: Immediately after injury; B: 6 h after injury; C: 12 h after injury; D: 24 h after injury. The black lines represent approximation of the edges over time, demonstrating the migration capacity of the cells.

and MMP9, two important metalloproteinases involved in the degradation of the extracellular matrix, thereby creating paths for the locomotion of cancer cells<sup>[31]</sup>.

Additionally, Amaar *et al.*<sup>[32]</sup> demonstrated that the over-expression of *PIWIL1* down-regulates the tumor suppressor gene *IGFBP5*, a member of the insulin-like growth factor binding protein family and whose expression is implicated in suppressing epithelial-mesenchymal transition and reducing the expression of E-cadherin and HIF1 $\alpha$ , indicating that it is critically related to cancer progression<sup>[33,34]</sup>.

Data obtained from our gene expression experiments also provided corroborating evidence that the *PIWIL1* gene plays a key role in cancer cell migration and invasion because several genes involved in these cellular processes were observed as DE when the cell lines were compared before and after *PIWIL1* knockout.


Many studies have demonstrated the oncogenic activities of the *DOCK2*, *ZNF503*, *PDE4D*, *ABL1*, *ABL2*, *LPAR1*, *SMAD2* and *WASF3* genes and their relation to tumor aggressiveness in several types of cancer, including gastric cancer<sup>[35-58]</sup>. Interestingly, *PIWIL1* knockout led to a decreased expression of these genes as well as an increased expression of the tumor suppressor gene *DACH1*, demonstrating that *PIWIL1* plays a crucial role in the pathway of development and progression of gastric cancer, and is likely a promising

candidate for therapeutic intervention.

Zhu *et al.*<sup>[53]</sup> reported that the over-expression of *DACH1* impaired the proliferation and invasion ability of lung adenocarcinoma cells *in vitro* via the down-regulation of *PRX3*, an oncoprotein required for the maintenance of mitochondrial function and tumorigenesis<sup>[59]</sup>. *DACH1* expression also inhibited epithelial-mesenchymal transition and metastasis by affecting TGF- $\beta$  signaling and decreased proliferation of cancer cells by inducing cell cycle arrest at the G2/M phase<sup>[60,61]</sup>.

Regarding the reported oncogenes, Rahrman *et al.*<sup>[37]</sup> observed that *PDE4D* is over-expressed in human prostate cancer and demonstrated that the knockdown of this gene reduced the growth and migration of prostate cancer cells *in vitro* as well as the growth and proliferation rate of prostate cancer xenografts *in vivo*<sup>[38]</sup>. Delyon *et al.*<sup>[39]</sup> demonstrated that *PDE4D* is also over-expressed in melanoma cell lines and pinpointed this gene as a regulator of cell invasion by interacting with *FAK* through *RACK1*, constituting a signaling pathway that when activated promotes tumor progression and metastasis<sup>[43]</sup>.

Recent studies have determined the role of ABL members from the tyrosine kinase family, *ABL1* and *ABL2*, in the development of many types of solid tumors. These proteins induce the activation of actin polymerization machinery by modulating the expression



**Figure 5** Analysis of the invasion capacity of the AGP01 cell line with and without the *PIWIL1* gene knockout. Statistically significant difference between groups was shown by the Student's *t* test ( $P < 0.001$ ). Photomicrography of the cell invasion assay demonstrating the decrease in the number of cells that invaded when *PIWIL1* was knocked out. NC: Negative control.

of several MMPs to promote morphological changes, including the formation of membrane protrusions and altered cell adhesion. Consequently, activation of ABL1 and ABL2 in cancer cells promote enhanced proliferation, migration and invasion, as well as drug resistance<sup>[39-42]</sup>.

*DOCK2* (dedicator of cytokinesis) belongs to the *DOCK* family of proteins and is expressed in hematopoietic cells<sup>[44]</sup>. According to Kulkarni *et al.*<sup>[45]</sup>, *DOCK2* has been reported to activate Rac, which is known to regulate several crucial processes, including lymphocyte migration, activation and differentiation of T cells<sup>[46]</sup>. Wang *et al.*<sup>[47]</sup> knocked out *DOCK2* in a B-cell lymphoma cell line and observed a decrease in Rac1 expression. Additionally, analysis of the growth curves of both cell lines demonstrated that the *DOCK2* knockout grew less than *DOCK2*, as evidenced by the lower cell proliferation.


*ZNF503* is expressed in the mammary gland and other tissues, and there is a high incidence of association between this gene deregulation and tumor aggressiveness in several kinds of tissues, such as lung, kidney and intestine<sup>[49]</sup>. Shahi *et al.*<sup>[48]</sup> performed scratch and 3D Matrigel culture assays in two mammary

epithelial cell lines to analyze the cell motility and migration. Both assays demonstrated that cell lines with *ZNF503* knockout migrated less, did not close the gaps, and inhibited invasiveness when compared to the control cells. These data indicate that *ZNF503* promotes cellular invasion and migration, and high levels of this gene are closely related with poor patient survival, breast cancer progression and increased metastasis.

Yu *et al.*<sup>[50]</sup> demonstrated that the *lysophosphatidic acid receptor 1 (LPAR1)* gene is related to migration and invasion in ascites from ovarian cancer and is expressed at higher levels in metastatic cell lines, when compared to non-metastatic cell lines. They also observed that the presence of high levels of lysophosphatidic acid are directly connected to cell migration stimulation, and *LPAR1* silencing reduced lysophosphatidic acid-induced invasion. Additionally, in breast tumors, a higher expression of *LPAR1* is related to a worse lung metastasis-free survival rate<sup>[51]</sup>.

Wiskott-Aldrich syndrome protein family 3 (*WASF3*) is an important gene, which has C-terminal domains that are responsible for actin polymerization activation, playing a role in cell proliferation and migration. The *WASF3* gene is normally over-expressed in several types





**Figure 6** Volcano plot comparing gene expression after *PIWIL1* permanent knockout in the gastric cancer AGP01 cell line. Differentially expressed probes [adjusted *P*-value of < 0.05 and |Log<sub>2</sub>(Fold-Change)| > 1] are on superior left and right areas (red). mRNAs involved in invasion and migration processes are in green.

of tumors, such as breast cancer, osteosarcoma and prostate cancer<sup>[52,53]</sup>. In gastric cancer, little is known about this gene; however, since micro (mi)RNAs and their targets are considered potential biomarkers for gastric cancer, Wang *et al.*<sup>[54]</sup> performed a luciferase assay and western blotting to investigate the relationship between miR-218 and *WASF3*. Their results demonstrated that over-expression of *WASF3* harms miR-218 and results in the inhibition of cell proliferation and migration, suggesting that *WASF3* is over-expressed in gastric cancer and induces cell proliferation and migration. Additionally, in qRT-PCR, *WASF3* mRNA expression levels were higher when compared to normal gastric cell lines.

Smad2 is the first intracellular protein in the signaling cascade of the TGF-β1 signaling pathway, which is involved in the progression of gastric cancer. In advanced stages of cancer, TGF-β1 acts as an oncogene, regulating multiple cellular functions, including stimulation of proliferation, differentiation and the inhibition of apoptosis<sup>[55,57]</sup>.

Interestingly, Lv *et al.*<sup>[56]</sup> observed that TGF-β1 levels in peritoneal lavage fluid are directly connected to peritoneal metastasis. Corroborating evidence was provided by Shinto *et al.*<sup>[58]</sup>, whose experiments demonstrated that p-Smad2 expression was higher in diffuse-type tumors and in peritoneal metastasis cases. Notably, the AGP01 cell line used to perform the *PIWIL1* knockout in our study was obtained from a patient with peritoneal metastasis, and we found *SMAD2* was over-expressed.

Taken together, these data reinforce the idea that *PIWIL1* plays a crucial role in the signaling pathway

of gastric cancer, regulating several genes involved in migration and invasion processes; therefore, its use as a therapeutic target may generate promising results in the treatment of gastric cancer, mainly in patients with peritoneal carcinomatosis, which is a condition associated with poor prognosis and a decreased overall survival.

## ARTICLE HIGHLIGHTS

### Research background

Gastric cancer (GC) remains a major public health problem, having the third highest incidence of death worldwide. *Piwi like RNA-mediated gene silencing 1* (*PIWIL1*) is involved in regulation of widespread biological processes, including stem cell proliferation, embryogenesis, growth, and development, and has been found to be frequently over-expressed in various tumor types, including GC. Previous studies have demonstrated that *PIWIL1* is implicated in improving tumor malignant behavior. *PIWIL1* expression has been shown to be absent in normal somatic tissues, making it a very intriguing target for therapy. We attempted to investigate the role of *PIWIL1* on the migration and invasion capacity of metastatic GC cells, using the AGP01 cell line, as well as checking the expression status of genes and proteins involved in these cellular processes, in order to elucidate the mechanisms by which *PIWIL1* provokes tumorigenic effects and to shed light on potential new strategies to target *PIWIL1*.

### Research motivation

Many aspects of gastric carcinogenesis remain elusive, and much effort has been made to improve patient prognosis. The *PIWIL1* has been identified as a novel extremely highly expressed gene in many types of cancer and its expression in GC tissue is related to poorer overall survival, suggesting that high expression of *PIWIL1* is associated with poor prognosis and that it could be used as a predictive marker or even a target for therapy. Although *PIWIL1* has been correlated with worse outcome, the involved mechanisms remain

unclear, and many hypotheses are being tested. Once the upstream and downstream signaling pathways of *PIWIL1* are elucidated, it will be possible to create new therapeutic strategies for gastric carcinogenesis, in order to improve the overall health of patients affected by this disease.

### Research objectives

We performed permanent knockout of the *PIWIL1* gene to verify phenotypic modifications in the AGP01 metastatic GC cell line, as well as alterations in expression level of mRNA and protein, in an attempt to better understand the mechanisms by which *PIWIL1* promotes tumor malignant behavior. This research demonstrates the importance of studying *PIWIL1* in GC, since data obtained through the achievement of our objectives showed that this protein has a crucial role in gastric carcinogenesis, promoting molecular and phenotypic alterations compatible with enhanced tumor aggressiveness. The elucidation of the role of *PIWIL1* protein in cancer cell invasion and migration will pave the way for developing potential clinical interventions, aiming to control GC dissemination.

### Research methods

We applied CRISPR/Cas9 technology to knockout the *PIWIL1* gene in a metastatic GC cell line, and analyzed its phenotypic modifications, as well as alterations in gene and protein expression. CRISPR-Cas9 technology was considered in 2015 as one of the most important technological advances of science. Mainly, it allows permanent silencing of the target gene and also creates a stable and permanent cell line with the desired modification. By this way, multiple experiments can be carried on, including long term evaluation of the downstream events caused by the molecular alteration, as well as discovering potential pathways influenced by the studied gene. Therefore, after permanent knockout of *PIWIL1* in the AGP01 cell line, we analyzed phenotypic modifications by performing wound-healing and Boyden chamber invasion assays, to assess migration and invasion, respectively. Moreover, aiming to shed light on the molecular mechanisms used by *PIWIL1* to make changes in the migration and invasion capability of cells, we carried out proteomic and microarray assays, using multidimensional protein identification technology (commonly known as MudPIT) and a one-color microarray-based gene expression analysis kit, respectively.

### Research results

*PIWIL1* gene knockout was successfully performed and confirmed by Sanger sequencing, which revealed an insertion of seven adenines in the *PIWIL1* gene sequence. *In silico* prediction of the encoded protein pointed to the appearance of a premature termination codon, suggesting that this insertion generates a truncated protein with a loss-of-function phenotype. *PIWIL1* knockout promoted a significant decrease in cell migration and invasion capacity ( $P < 0.01$  and  $P < 0.001$ , respectively), which is consistent with data present in the literature demonstrating that this protein is implicated in several signaling pathways that regulate cell motility. By comparing expression profiles after *PIWIL1* knockout, a total of 251 mRNA were found to be differentially expressed, with 43 up-regulated and 208 down-regulated mRNA. A functional analysis grouping all differentially expressed mRNAs demonstrated that 35 genes encoded proteins were involved in invasion and migration cellular processes. After extensive review of data presented in the literature, we selected 9 of these 35 genes (*DOCK2*, *ZNF503*, *PDE4D*, *ABL1*, *ABL2*, *LPAR1*, *SMAD2*, *WASF3* and *DACH1*) as possibly related to the mechanisms used by *PIWIL1* to promote carcinogenic effects related to migration and invasion, since their functions are consistent with the changes observed (being up- or down-regulated after knockout). Additionally, the analysis of proteomic data revealed that *PIWIL1* knockout caused modification in the expression of 27 proteins involved in epithelial-mesenchymal transition (EMT). Twenty-two oncoproteins related to EMT promotion, including *FGFR1*, *PCNA*, *ACTN4*, *GSN* and *TUBB3*, were expressed in the AGP01 cell line before knockout and reduced to a level that were not detectable by the technique after knockout. On the other hand, *PIWIL1* knockout caused an increase in the expression of six proteins implicated in EMT suppression, such as *ACSM3*, *ADGRG1* and *ANPEP*, that were absent in AGP01 before knockout. To the best of our knowledge, this is the first report describing molecular alteration compatible with phenotypic alterations after permanent knockout of *PIWIL1* in GC. Detailed mechanisms leading to *PIWIL1* over-expression in cancer as well as the pathways by which this protein

improves the malignant phenotype should be further investigated.

### Research conclusions

In the current study, we pioneered the performance of an *in vitro* knockout of the *PIWIL1* gene by using the CRISPR-Cas9 system, and found that absence of this gene significantly impaired the migration and invasion capacity of the AGP01 cell line, besides modifying mRNA and protein expression of potential molecular targets involved in the EMT process. The results of such experiments contributed to understanding of the mechanisms used by *PIWIL1* to promote alteration in migration and invasion capacity of gastric cells during tumorigenesis, and also revealed the participation of new players related to *PIWIL1* expression, such as *FGFR1*, *PCNA*, *ACTN4*, *PDE4D* and *SMAD2*. Our results demonstrated that knockout of *PIWIL1* promotes several changes in cell phenotype, suggesting the critical role of the *PIWIL1* oncogene in GC, and confirmed the hypothesis that *PIWIL1* expression provokes migration, invasiveness and EMT as potential mechanisms of improved tumor aggressiveness. The presented findings open new perspectives for molecular interventions in GC.

### Research perspectives

Definite silencing of *PIWIL1* by the CRISPR-Cas9 system resulted in robust findings favoring the discovery of new mechanisms involved in gastric carcinogenesis. The presented results must be validated by other researchers, and if confirmed, might lead to innovative interventions aiming to treat GC.

## REFERENCES

- 1 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; **136**: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]
- 2 Wu HH, Lin WC, Tsai KW. Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. *Expert Rev Mol Med* 2014; **16**: e1 [PMID: 24456939 DOI: 10.1017/erm.2013.16]
- 3 Assumpção CB, Calcagno DQ, Araújo TM, Santos SE, Santos ÂK, Riggins GJ, Burbano RR, Assumpção PP. The role of piRNA and its potential clinical implications in cancer. *Epigenomics* 2015; **7**: 975-984 [PMID: 25929784 DOI: 10.2217/epi.15.37]
- 4 Navarro A, Tejero R, Viñolas N, Cordeiro A, Marrades RM, Fuster D, Caritg O, Moises J, Muñoz C, Molins L, Ramirez J, Monzo M. The significance of PIWI family expression in human lung embryogenesis and non-small cell lung cancer. *Oncotarget* 2015; **6**: 31544-31556 [PMID: 25742785 DOI: 10.18632/oncotarget.3003]
- 5 Tan Y, Liu L, Liao M, Zhang C, Hu S, Zou M, Gu M, Li X. Emerging roles for PIWI proteins in cancer. *Acta Biochim Biophys Sin (Shanghai)* 2015; **47**: 315-324 [PMID: 25854579 DOI: 10.1093/abbs/gmv018]
- 6 Siddiqi S, Matushansky I. Piwis and piwi-interacting RNAs in the epigenetics of cancer. *J Cell Biochem* 2012; **113**: 373-380 [PMID: 21928326 DOI: 10.1002/jcb.23363]
- 7 Siddiqi S, Terry M, Matushansky I. Hiwi mediated tumorigenesis is associated with DNA hypermethylation. *PLoS One* 2012; **7**: e33711 [PMID: 22438986 DOI: 10.1371/journal.pone.0033711]
- 8 Litwin M, Szczepańska-Buda A, Piotrowska A, Dzięgiel P, Witkiewicz W. The meaning of PIWI proteins in cancer development. *Oncol Lett* 2017; **13**: 3354-3362 [PMID: 28529570 DOI: 10.3892/ol.2017.5932]
- 9 Li C, Zhou X, Chen J, Lu Y, Sun Q, Tao D, Hu W, Zheng X, Bian S, Liu Y, Ma Y. *PIWIL1* destabilizes microtubule by suppressing phosphorylation at Ser16 and RLIM-mediated degradation of Stathmin1. *Oncotarget* 2015; **6**: 27794-27804 [PMID: 26317901 DOI: 10.18632/oncotarget.4533]
- 10 Chen Z, Che Q, He X, Wang F, Wang H, Zhu M, Sun J, Wan X. Stem cell protein Piwil1 endowed endometrial cancer cells with stem-like properties via inducing epithelial-mesenchymal transition. *BMC Cancer* 2015; **15**: 811 [PMID: 26506848 DOI: 10.1186/

- s12885-015-1794-8]
- 11 **Wang Y**, Liu Y, Shen X, Zhang X, Chen X, Yang C, Gao H. The PIWI protein acts as a predictive marker for human gastric cancer. *Int J Clin Exp Pathol* 2012; **5**: 315-325 [PMID: 22670175]
  - 12 **Liu X**, Sun Y, Guo J, Ma H, Li J, Dong B, Jin G, Zhang J, Wu J, Meng L, Shou C. Expression of hiwi gene in human gastric cancer was associated with proliferation of cancer cells. *Int J Cancer* 2006; **118**: 1922-1929 [PMID: 16287078 DOI: 10.1002/ijc.21575]
  - 13 **Riordan SM**, Heruth DP, Zhang LQ, Ye SQ. Application of CRISPR/Cas9 for biomedical discoveries. *Cell Biosci* 2015; **5**: 33 [PMID: 26137216 DOI: 10.1186/s13578-015-0027-9]
  - 14 **Hsu PD**, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. *Cell* 2014; **157**: 1262-1278 [PMID: 24906146 DOI: 10.1016/j.cell.2014.05.010]
  - 15 **Jinek M**, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* 2012; **337**: 816-821 [PMID: 22745249 DOI: 10.1126/science.1225829]
  - 16 **Chen S**, Sun H, Miao K, Deng CX. CRISPR-Cas9: from Genome Editing to Cancer Research. *Int J Biol Sci* 2016; **12**: 1427-1436 [PMID: 27994508 DOI: 10.7150/ijbs.17421]
  - 17 **Kawahara A**, Hisano Y, Ota S, Taimatsu K. Site-Specific Integration of Exogenous Genes Using Genome Editing Technologies in Zebrafish. *Int J Mol Sci* 2016; **17** [PMID: 27187373 DOI: 10.3390/ijms17050727]
  - 18 **Maeder ML**, Gersbach CA. Genome-editing Technologies for Gene and Cell Therapy. *Mol Ther* 2016; **24**: 430-446 [PMID: 26755333 DOI: 10.1038/mt.2016.10]
  - 19 **Travis J**. Breakthrough of the Year: CRISPR makes the cut. *Science Magazine* 2015; Available from: URL: <http://www.sciencemag.org/news/2015/12/and-science-s-breakthrough-year>
  - 20 **Leal MF**, Martins do Nascimento JL, da Silva CE, Vita Lamarão MF, Calcagno DQ, Khayat AS, Assumpção PP, Cabral IR, de Arruda Cardoso Smith M, Burbano RR. Establishment and conventional cytogenetic characterization of three gastric cancer cell lines. *Cancer Genet Cytogenet* 2009; **195**: 85-91 [PMID: 19837275 DOI: 10.1016/j.cancergencyto.2009.04.020]
  - 21 **Liehr T**, Heller A, Starke H, Rubtsov N, Trifonov V, Mrasek K, Weise A, Kuechler A, Claussen U. Microdissection based high resolution multicolor banding for all 24 human chromosomes. *Int J Mol Med* 2002; **9**: 335-339 [PMID: 11891523]
  - 22 **Liehr T**. The Standard FISH Procedure. Fluorescence In Situ Hybridization (FISH) - Application Guide. Berlin: *Springer* 2017; 109-118
  - 23 **Benjamini Y**, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J Royal Stat Soc* 1995; **57**: 289-300
  - 24 **Carlson M**. org.Hs.eg.db: Genome wide annotation for Human. 2017; R package version 3.5.0
  - 25 **Falcon S**, Gentleman R. Using GOSTats to test gene lists for GO term association. *Bioinformatics* 2007; **23**: 257-258 [PMID: 17098774 DOI: 10.1093/bioinformatics/btl567]
  - 26 **Xie K**, Zhang K, Kong J, Wang C, Gu Y, Liang C, Jiang T, Qin N, Liu J, Guo X, Huo R, Liu M, Ma H, Dai J, Hu Z. Cancer-testis gene PIWIL1 promotes cell proliferation, migration, and invasion in lung adenocarcinoma. *Cancer Med* 2018; **7**: 157-166 [PMID: 29168346 DOI: 10.1002/cam4.1248]
  - 27 **Sun R**, Gao CL, Li DH, Li BJ, Ding YH. Expression Status of PIWIL1 as a Prognostic Marker of Colorectal Cancer. *Dis Markers* 2017; **2017**: 1204937 [PMID: 28634417 DOI: 10.1155/2017/1204937]
  - 28 **Bloomfield M**, Duesberg P. Karyotype alteration generates the neoplastic phenotypes of SV40-infected human and rodent cells. *Mol Cytogenet* 2015; **8**: 79 [PMID: 26500699 DOI: 10.1186/s13039-015-0183-y]
  - 29 **Gebhart E**, Liehr T. Patterns of genomic imbalances in human solid tumors (Review). *Int J Oncol* 2000; **16**: 383-399 [PMID: 10639584]
  - 30 **Wang X**, Tong X, Gao H, Yan X, Xu X, Sun S, Wang Q, Wang J. Silencing HIWI suppresses the growth, invasion and migration of glioma cells. *Int J Oncol* 2014; **45**: 2385-2392 [PMID: 25269862 DOI: 10.3892/ijo.2014.2673]
  - 31 **Rundhaug JE**. Matrix metalloproteinases and angiogenesis. *J Cell Mol Med* 2005; **9**: 267-285 [PMID: 15963249]
  - 32 **Amaar YG**, Baylink DJ, Mohan S. Ras-association domain family 1 protein, RASSF1C, is an IGFBP-5 binding partner and a potential regulator of osteoblast cell proliferation. *J Bone Miner Res* 2005; **20**: 1430-1439 [PMID: 16007340 DOI: 10.1359/JBMR.050311]
  - 33 **Wang J**, Ding N, Li Y, Cheng H, Wang D, Yang Q, Deng Y, Yang Y, Li Y, Ruan X, Xie F, Zhao H, Fang X. Insulin-like growth factor binding protein 5 (IGFBP5) functions as a tumor suppressor in human melanoma cells. *Oncotarget* 2015; **6**: 20636-20649 [PMID: 26010068 DOI: 10.18632/oncotarget.4114]
  - 34 **Güllü G**, Karabulut S, Akkiprik M. Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers. *Chin J Cancer* 2012; **31**: 266-280 [PMID: 22313597 DOI: 10.5732/cjc.011.10405]
  - 35 **Henry C**, Llamas E, Knipprath-Meszaros A, Schoetza A, Obermann E, Fuenfschilling M, Caduff R, Fink D, Hacker N, Ward R, Heinzelmann-Schwarz V, Ford C. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. *Oncotarget* 2015; **6**: 40310-40326 [PMID: 26515598 DOI: 10.18632/oncotarget.5643]
  - 36 **Henry CE**, Llamas E, Djordjevic A, Hacker NF, Ford CE. Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer. *Oncogenesis* 2016; **5**: e226 [PMID: 27239958 DOI: 10.1038/ncis.2016.32]
  - 37 **Rahrmann EP**, Collier LS, Knutson TP, Doyal ME, Kuslak SL, Green LE, Malinowski RL, Roethe L, Akagi K, Waknitz M, Huang W, Largaespada DA, Marker PC. Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. *Cancer Res* 2009; **69**: 4388-4397 [PMID: 19401450 DOI: 10.1158/0008-5472.CAN-08-3901]
  - 38 **Delyon J**, Servy A, Laugier F, André J, Ortonne N, Battistella M, Mourah S, Bensussan A, Lebbé C, Dumaz N. PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma. *Oncogene* 2017; **36**: 3252-3262 [PMID: 28092671 DOI: 10.1038/onc.2016.469]
  - 39 **Greuber EK**, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukaemia to solid tumours. *Nat Rev Cancer* 2013; **13**: 559-571 [PMID: 23842646 DOI: 10.1038/nrc3563]
  - 40 **Wang J**, Pendergast AM. The Emerging Role of ABL Kinases in Solid Tumors. *Trends Cancer* 2015; **1**: 110-123 [PMID: 26645050 DOI: 10.1016/j.trecan.2015.07.004]
  - 41 **Gu JJ**, Rouse C, Xu X, Wang J, Onaitis MW, Pendergast AM. Inactivation of ABL kinases suppresses non-small cell lung cancer metastasis. *JCI Insight* 2016; **1**: e89647 [PMID: 28018973 DOI: 10.1172/jci.insight.89647]
  - 42 **Wang J**, Rouse C, Jasper JS, Pendergast AM. ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling. *Sci Signal* 2016; **9**: ra12 [PMID: 26838548 DOI: 10.1126/scisignal.aad3210]
  - 43 **Sulzmaier FJ**, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. *Nat Rev Cancer* 2014; **14**: 598-610 [PMID: 25098269 DOI: 10.1038/nrc3792]
  - 44 **Tajiri H**, Urano T, Shirai T, Takaya D, Matsunaga S, Setoyama D, Watanabe M, Kukimoto-Niino M, Oisaki K, Ushijima M, Sanematsu F, Honma T, Terada T, Oki E, Shirasawa S, Maehara Y, Kang D, Côté JF, Yokoyama S, Kanai M, Fukui Y. Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK1. *Cell Rep* 2017; **19**: 969-980 [PMID: 28467910 DOI: 10.1016/j.celrep.2017.04.016]
  - 45 **Kulkarni K**, Yang J, Zhang Z, Barford D. Multiple factors confer specific Cdc42 and Rac protein activation by dedicator of cytokinesis (DOCK) nucleotide exchange factors. *J Biol Chem* 2011; **286**: 25341-25351 [PMID: 21613211 DOI: 10.1074/jbc.M111.236455]
  - 46 **Wu M**, Small D, Duffield AS. DOCK2: A novel FLT3/ITD

- leukemia drug target. *Oncotarget* 2017; **8**: 88253-88254 [PMID: 29179430 DOI: 10.18632/oncotarget.21390]
- 47 **Wang L**, Nishihara H, Kimura T, Kato Y, Tanino M, Nishio M, Obara M, Endo T, Koike T, Tanaka S. DOCK2 regulates cell proliferation through Rac and ERK activation in B cell lymphoma. *Biochem Biophys Res Commun* 2010; **395**: 111-115 [PMID: 20350533 DOI: 10.1016/j.bbrc.2010.03.148]
- 48 **Shahi P**, Slorach EM, Wang CY, Chou J, Lu A, Ruderisch A, Werb Z. The Transcriptional Repressor ZNF503/Zeppo2 Promotes Mammary Epithelial Cell Proliferation and Enhances Cell Invasion. *J Biol Chem* 2015; **290**: 3803-3813 [PMID: 25538248 DOI: 10.1074/jbc.M114.611202]
- 49 **Shahi P**, Wang CY, Lawson DA, Slorach EM, Lu A, Yu Y, Lai MD, Gonzalez Velozo H, Werb Z. ZNF503/Zpo2 drives aggressive breast cancer progression by down-regulation of GATA3 expression. *Proc Natl Acad Sci USA* 2017; **114**: 3169-3174 [PMID: 28258171 DOI: 10.1073/pnas.1701690114]
- 50 **Yu X**, Zhang Y, Chen H. LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study. *BMC Cancer* 2016; **16**: 846 [PMID: 27809800 DOI: 10.1186/s12885-016-2865-1]
- 51 **Sahay D**, Leblanc R, Grunewald TG, Ambatipudi S, Ribeiro J, Clézardin P, Peyruchaud O. The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. *Oncotarget* 2015; **6**: 20604-20620 [PMID: 26098771 DOI: 10.18632/oncotarget.3774]
- 52 **Teng Y**, Ghoshal P, Ngoka L, Mei Y, Cowell JK. Critical role of the WASF3 gene in JAK2/STAT3 regulation of cancer cell motility. *Carcinogenesis* 2013; **34**: 1994-1999 [PMID: 23677069 DOI: 10.1093/carcin/bgt167]
- 53 **Zhu Z**, Chen W, Yin X, Lai J, Wang Q, Liang L, Wang W, Wang A, Zheng C. WAVE3 Induces EMT and Promotes Migration and Invasion in Intrahepatic Cholangiocarcinoma. *Dig Dis Sci* 2016; **61**: 1950-1960 [PMID: 26971088 DOI: 10.1007/s10620-016-4102-9]
- 54 **Wang G**, Fu Y, Liu G, Ye Y, Zhang X. miR-218 Inhibits Proliferation, Migration, and EMT of Gastric Cancer Cells by Targeting WASF3. *Oncol Res* 2017; **25**: 355-364 [PMID: 27642088 DOI: 10.3727/096504016X14738114257367]
- 55 **Lv ZD**, Wang HB, Li FN, Wu L, Liu C, Nie G, Kong B, Qu HL, Li JG. TGF- $\beta$ 1 induces peritoneal fibrosis by activating the Smad2 pathway in mesothelial cells and promotes peritoneal carcinomatosis. *Int J Mol Med* 2012; **29**: 373-379 [PMID: 22139024 DOI: 10.3892/ijmm.2011.852]
- 56 **Lv ZD**, Na D, Ma XY, Zhao C, Zhao WJ, Xu HM. Human peritoneal mesothelial cell transformation into myofibroblasts in response to TGF- $\beta$ 1 in vitro. *Int J Mol Med* 2011; **27**: 187-193 [PMID: 21152863 DOI: 10.3892/ijmm.2010.574]
- 57 **Wu Y**, Li Q, Zhou X, Yu J, Mu Y, Munker S, Xu C, Shen Z, Müllenbach R, Liu Y, Li L, Gretz N, Zieker D, Li J, Matsuzaki K, Li Y, Dooley S, Weng H. Decreased levels of active SMAD2 correlate with poor prognosis in gastric cancer. *PLoS One* 2012; **7**: e35684 [PMID: 22539990 DOI: 10.1371/journal.pone.0035684]
- 58 **Shinto O**, Yashiro M, Toyokawa T, Nishii T, Kaizaki R, Matsuzaki T, Noda S, Kubo N, Tanaka H, Doi Y, Ohira M, Muguruma K, Sawada T, Hirakawa K. Phosphorylated smad2 in advanced stage gastric carcinoma. *BMC Cancer* 2010; **10**: 652 [PMID: 21110833 DOI: 10.1186/1471-2407-10-652]
- 59 **Song IS**, Jeong YJ, Jeong SH, Heo HJ, Kim HK, Bae KB, Park YH, Kim SU, Kim JM, Kim N, Ko KS, Rhee BD, Han J. FOXM1-Induced PRX3 Regulates Stemness and Survival of Colon Cancer Cells via Maintenance of Mitochondrial Function. *Gastroenterology* 2015; **149**: 1006-1016.e9 [PMID: 26091938 DOI: 10.1053/j.gastro.2015.06.007]
- 60 **Bu XN**, Qiu C, Wang C, Jiang Z. Inhibition of DACH1 activity by short hairpin RNA represses cell proliferation and tumor invasion in pancreatic cancer. *Oncol Rep* 2016; **36**: 745-754 [PMID: 27278537 DOI: 10.3892/or.2016.4843]
- 61 **Yan W**, Wu K, Herman JG, Brock MV, Zhou Y, Lu Y, Zhang Z, Yang Y, Guo M. Epigenetic silencing of DACH1 induces the invasion and metastasis of gastric cancer by activating TGF- $\beta$  signalling. *J Cell Mol Med* 2014; **18**: 2499-2511 [PMID: 24912879 DOI: 10.1111/jcmm.12325]

**P- Reviewer:** Chen Z, Kimura A, Matowicka-Karna J, Park WS  
**S- Editor:** Wang XJ **L- Editor:** Filipodia **E- Editor:** Huang Y





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>



ISSN 1007-9327

